地图状萎缩四年视力下降的决定因素:年龄相关性眼病研究及年龄相关性眼病研究2分析
该研究对年龄相关性眼病研究(AREDS)和AREDS2中继发于非渗出性年龄相关性黄斑变性的地图状萎缩(GA)眼进行二次分析,纳入1351眼(994例),其中594眼有4年最佳矫正视力(BCVA)随访。基线BCVA较高、基线GA距黄斑中心凹较近和GA增长较快均独立与4年BCVA下降较大相关(各P<0.001)。基线BCVA≥40字母且GA累及或距中心凹1 mm以内的483眼4年BCVA显著下降(平均变化-11.33字母[95%CI -12.80至-9.84]),作者认为这些眼可能从延缓GA进展的治疗中获益更多。
要点
- 基线BCVA较高、GA距中心凹较近和GA增长较快均独立与4年BCVA下降较大相关(各P<0.001)。
- 基线BCVA≥40字母且GA累及或距中心凹1 mm以内的483眼4年BCVA显著下降,平均变化-11.33字母(95%CI -12.80至-9.84)。
- 基线BCVA<40字母的69眼和基线GA距中心凹>1 mm的42眼4年BCVA无显著下降。
核心结论
- 在该队列中,GA累及或距中心凹1 mm以内且基线BCVA≥40字母的眼更可能出现显著BCVA下降,提示这些眼可能从延缓GA进展的治疗中获益更多。
- 研究结果支持对GA患者采取个性化管理,并可能指导未来GA试验的设计。
研究设计与样本
- 两项随机对照临床试验的二次分析。
- 纳入AREDS和AREDS2中继发于非渗出性年龄相关性黄斑变性的GA参与者。
- 共纳入994例参与者的1351眼,其中464例参与者的594眼有4年BCVA随访。
- 基线和每年彩色眼底照相评估GA面积及距黄斑中心凹距离,BCVA采用早期治疗糖尿病视网膜病变研究logMAR视力表测量。
- 采用多变量线性混合效应模型分析BCVA下降与GA进展及其他基线因素的关系。
主要发现
- 基线BCVA较高、基线GA距黄斑中心凹较近和GA增长率较大均独立与4年BCVA下降较大相关(各P<0.001)。
- 594眼中,基线BCVA<40字母(Snellen等效20/160或更差)的69眼和基线GA距黄斑中心凹>1 mm的42眼4年BCVA无显著下降。
- 同时满足基线BCVA≥40字母和GA病灶累及或距黄斑中心凹1 mm以内的483眼4年BCVA显著下降,平均变化-11.33字母(95%CI -12.80至-9.84)。
- 在该483眼中,GA进展较快与BCVA下降较大相关(P<0.001)。
关键数值与推荐
- 基线BCVA<40字母(Snellen等效20/160或更差)的69眼4年BCVA无显著下降。
- 基线GA距黄斑中心凹>1 mm的42眼4年BCVA无显著下降。
- 基线BCVA≥40字母且GA累及或距黄斑中心凹1 mm以内的483眼4年BCVA显著下降,平均变化-11.33字母(95%CI -12.80至-9.84)。
- 基线BCVA较高、基线GA距黄斑中心凹较近和GA增长率较大与4年BCVA下降较大独立相关(各P<0.001)。
临床怎么用
- 作者认为,GA累及或距黄斑中心凹1 mm以内且基线BCVA≥40字母的眼可能从延缓GA进展的治疗中获益更多。
- 作者认为,研究结果支持对GA患者采取个性化管理,并可能指导未来GA试验的设计。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the relationship between geographic atrophy (GA) progression and change in best-corrected visual acuity (BCVA) over 4 years and identify factors associated with faster BCVA loss. DESIGN: Secondary analysis of 2 randomized controlled clinical trials. PARTICIPANTS: Age-Related Eye Disease Study (AREDS) and AREDS2 participants with GA secondary to nonexudative age-related macular degeneration. METHODS: Baseline and annual color fundus photographs were assessed for GA area and proximity to the foveal center. Best-corrected visual acuity was measured using Early Treatment Diabetic Retinopathy Study logarithm of the minimum angle of resolution (logMAR) charts. Analyses included BCVA change over 4 years, with the relationship of BCVA decline with GA progression and other baseline factors examined using multivariable linear mixed-effects models. MAIN OUTCOME MEASURES: The primary outcome was BCVA change over 4 years. Secondary outcomes included BCVA change from baseline to years 1, 2, and 3. RESULTS: We included 1351 eyes from 994 participants, including 594 eyes from 464 participants with 4-year BCVA follow-up. Higher baseline BCVA, smaller baseline GA proximity to the foveal center, and greater GA growth rate were each independently associated with larger BCVA loss over 4 years (each P < 0.001). Among the 594 eyes with 4-year BCVA data, 69 eyes with a baseline BCVA < 40 letters (Snellen equivalent of 20/160 or worse) and 42 eyes with baseline GA located more than 1 mm from the foveal center did not experience significant BCVA loss over 4 years. In contrast, 483 eyes that met both criteria of baseline BCVA ≥ 40 letters and GA lesions involving or within 1 mm of the foveal center showed significant BCVA loss over 4 years (mean change = -11.33 letters [95% confidence interval = -12.80 to -9.84]), with faster GA progression associated with larger BCVA loss (P < 0.001). CONCLUSIONS: In this cohort, eyes with GA involving or within 1 mm of the foveal center and a baseline BCVA of ≥ 40 letters appeared more likely to experience significant BCVA loss, suggesting these eyes may benefit more from therapies that slow GA progression. Our findings support a personalized approach to managing patients with GA, potentially guiding the design of future GA trials. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.
引用
- Shen LL, Kaiser PK, Liu J, et al. Determinants of Four-Year Visual Acuity Loss in Geographic Atrophy: An Analysis of Age-Related Eye Disease Study and Age-Related Eye Disease Study 2. Ophthalmology. 2025. PMID: 39921001. doi:10.1016/j.ophtha.2025.01.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。